Polycystic ovary syndrome and insulin: Our understanding in the past, present and future

Women's Health

Volumn 11, Issue 2, 2015, Pages 137-149

  Mayer, Stéphanie B ^a   Evans, William S ^b   Nestler, John E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cardiovascular disease risk; infertility; insulin; insulin resistance; metformin; PCOS

Indexed keywords

CLOMIFENE; CLOMIFENE CITRATE; GLUCOSE; INSULIN; LETROZOLE; METFORMIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; ANDROGEN; ANTIDIABETIC AGENT;

ABSENCE OF SIDE EFFECTS; ANOVULATION; BODY MASS; CARDIOVASCULAR DISEASE; DIAGNOSTIC IMAGING; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; HYPERTENSION; INSULIN RESISTANCE; LACTATION; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PHYSIOLOGY; WOMEN'S HEALTH;

ANDROGENS; ANOVULATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; WOMEN'S HEALTH;

EID: 84925096868     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.73     Document Type: Review

References (90)

1. Stein AL. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191 (1935).
2. Zawadzki Jk DA. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. NIH Expert Conference on PCOS 1991, 377-384 (1992).
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19-25 (2004).
4. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab. 91(3), 781-785 (2006).
5. Franks S. Polycystic ovary syndrome. N. Engl. J. Med. 333(13), 853-861 (1995).
6. Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust. NZ J. Obstet. Gynaecol. 45(1), 17-19 (2005).
7. Azziz R, Carmina E, Dewailly D et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91(2), 456-488 (2009).
8. Kahn CR, Flier JS, Bar RS et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N. Engl. J. Med. 294(14), 739-745 (1976).
9. Taylor SI, Dons RF, Hernandez E, Roth J, Gorden P. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann. Intern. Med. 97(6), 851-855 (1982).
10. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50(1), 113-116 (1980).
11. Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83(6), 2001-2005 (1998).
12. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 335(9), 617-623 (1996).
13. Nestler JE, Barlascini CO, Matt DW et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68(6), 1027-1032 (1989).
14. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20(4), 535-582 (1999).
15. Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 43(1), 123-147 (2014).
16. Imperato-Mcginley J, Peterson RE, Sturla E, Dawood Y, Bar RS. Primary amenorrhea associated with hirsutism, acanthosis nigricans, dermoid cysts of the ovaries and a new type of insulin resistance. Am. J. Med. 65(2), 389-395 (1978).
17. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am. J. Obstet. Gynecol. 154(2), 384-389 (1986).
18. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil. Steril. 45(3), 327-333 (1986).
19. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 70(3), 699-704 (1990).
20. rd et al. Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history. J. Pediatr. 107(6), 893-897 (1985).
21. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin. Endocrinol. Metab. 67(3), 460-464 (1988).
22. Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 72(1), 83-89 (1991).
23. Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J. Clin. Invest. 83(1), 23-29 (1989).
24. Smith S, Ravnikar VA, Barbieri RL. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. Fertil. Steril. 48(1), 72-77 (1987).
25. Nestler JE, Singh R, Matt DW, Clore JN, Blackard WG. Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. Am. J. Obstet. Gynecol. 163(4 Pt 1), 1243-1246 (1990).
26. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with Type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 52(1), 81-86 (2000).
27. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with Type 2 diabetes. Diabetes Care 24(6), 1050-1052 (2001).
28. Escobar-Morreale HF, Roldan B, Barrio R et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with Type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 85(11), 4182-4187 (2000).
29. Zachurzok A, Deja G, Gawlik A, Drosdzol-Cop A, Malecka-Tendera E. Hyperandrogenism in adolescent girls with Type 1 diabetes mellitus treated with intensive and continuous subcutaneous insulin therapy. Endokrynol. Pol. 64(2), 121-128 (2013).
30. Miyoshi A, Nagai S, Takeda M et al. Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with Type 1 diabetes mellitus. J. Diabetes Invest. 4(3), 326-329 (2013).
31. Codner E, Cassorla F. Puberty and ovarian function in girls with Type 1 diabetes mellitus. Horm. Res. 71(1), 12-21 (2009).
32. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 57(2), 356-359 (1983).
33. Toprak S, Yonem A, Cakir B et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm. Res. 55(2), 65-70 (2001).
34. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9), 1165-1174 (1989).
35. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84(1), 165-169 (1999).
36. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22(1), 141-146 (1999).
37. Solomon CG, Hu FB, Dunaif A et al. Long or highly irregular menstrual cycles as a marker for risk of Type 2 diabetes mellitus. JAMA 286(19), 2421-2426 (2001).
38. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(5), 2031-2036 (2003).
39. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil. Steril. 66(6), 942-947 (1996).
40. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of Type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90(1), 66-71 (2005).
41. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. J. Clin. Endocrinol. Metab. 92(12), 4546-4556 (2007).
42. Legro RS, Arslanian SA, Ehrmann DA et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98(12), 4565-4592 (2013).
43. Celik C, Abali R, Bastu E, Tasdemir N, Tasdemir UG, Gul A. Assessment of impaired glucose tolerance prevalence with hemoglobin A(1)c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study. Hum. Reprod. 28(4), 1062-1068 (2013).
44. Velling Magnussen L, Mumm H, Andersen M, Glintborg D. Hemoglobin A1c as a tool for the diagnosis of Type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertil. Steril. 96(5), 1275-1280 (2011).
45. Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL, Sood A. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil. Steril. 96(4), 1043-1047 (2011).
46. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83(8), 2694-2698 (1998).
47. Moran LJ, Ko H, Misso M et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J. Acad. Nutr. Diet. 113(4), 520-545 (2013).
48. Sharma ST, Wickham EP 3rd, Nestler JE. Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr. Pract. 13(4), 373-379 (2007).
49. Talbott E, Clerici A, Berga SL et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J. Clin. Epidemiol. 51(5), 415-422 (1998).
50. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111(8), 607-613 (2001).
51. Talbott EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20(11), 2414-2421 (2000).
52. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(6), 2562-2568 (2003).
53. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann. Intern. Med. 126(1), 32-35 (1997).
54. Orio F, Jr., Palomba S, Cascella T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89(9), 4588-4593 (2004).
55. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49(4), 403-414 (2007).
56. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90(4), 1929-1935 (2005).
57. Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Anthropometric and biochemical characteristics of polycystic ovarian syndrome in South Indian women using AES-2006 criteria. Int. J. Endocrinol. Metabol. 12(1), e12470 (2014).
58. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol. 60(1), 39-51 (2008).
59. Chekir C, Nakatsuka M, Kamada Y, Noguchi S, Sasaki A, Hiramatsu Y. Impaired uterine perfusion associated with metabolic disorders in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 84(2), 189-195 (2005).
60. Solomon CG, Hu FB, Dunaif A et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J. Clin. Endocrinol. Metab. 87(5), 2013-2017 (2002).
61. Shaw LJ, Bairey Merz CN, Azziz R et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 93(4), 1276-1284 (2008).
62. Pierpoint T, Mckeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol. 51(7), 581-586 (1998).
63. Mani H, Levy MJ, Davies MJ et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. (Oxf.) 78(6), 926-934 (2013).
64. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038-2049 (2010).
65. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J. Clin. Endocrinol. Metab. 83(9), 3078-3082 (1998).
66. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85(7), 2434-2438 (2000).
67. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod. Biol. Endocrinol. 1, 109 (2003).
68. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. 138(3), 269-274 (1998).
69. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338(26), 1876-1880 (1998).
70. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. 82(4), 893-902 (2004).
71. Palomba S, Orio F Jr, Falbo A et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90(7), 4068-4074 (2005).
72. Misso ML, Costello MF, Garrubba M et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 19(1), 2-11 (2013).
73. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327(7421), 951-953 (2003).
74. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum. Reprod. 19(11), 2474-2483 (2004).
75. Creanga AA, Bradley HM, Mccormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet. Gynecol. 111(4), 959-968 (2008).
76. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, Cd003053 (2012).
77. Legro RS, Barnhart HX, Schlaff WD et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356(6), 551-566 (2007).
78. Morin-Papunen L, Rantala AS, Unkila-Kallio L et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97(5), 1492-1500 (2012).
79. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87(2), 524-529 (2002).
80. De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur. J. Obstet. Gynecol. Reprod. Biol. 157(1), 63-66 (2011).
81. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med. 358(19), 2003-2015 (2008).
82. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod. 19(6), 1323-1330 (2004).
83. Vanky E, Stridsklev S, Heimstad R et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J. Clin. Endocrinol. Metab. 95(12), E448-E455 (2010).
84. Eyal S, Easterling TR, Carr D et al. Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 38(5), 833-840 (2010).
85. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. Diabetologia 45(11), 1509-1514 (2002).
86. Vanky E, Nordskar JJ, Leithe H, Hjorth-Hansen AK, Martinussen M, Carlsen SM. Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. BJOG 119(11), 1403-1409 (2012).
87. Kulkarni AD, Jamieson DJ, Jones HW, Jr et al. Fertility treatments and multiple births in the United States. N. Engl. J. Med. 369(23), 2218-2225 (2013).
88. Abd Elgafor I. Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. Arch. Gynecol. Obstet. 288(1), 119-123 (2013).
89. Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil. Steril. 94(4), 1405-1409 (2010).
90. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum. Reprod. 21(6), 1432-1435 (2006).